Availability of hepatitis B vaccine that does not contain thimerosal as a preservative

Morbidity and Mortality Weekly Report

Volumn 48, Issue 35, 1999, Pages 780-782

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; PRESERVATIVE; THIOMERSAL;

ARTICLE; UNITED STATES;

HEPATITIS B VACCINES; PRESERVATIVES, PHARMACEUTICAL; THIMEROSAL; UNITED STATES;

EID: 0033543276     PISSN: 01492195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. CDC. Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR 1999;48:533-5.
2. American Academy of Pediatrics. Thimerosal in vaccines: an interim report to clinicians. AAP News 1999;15:10-2.
3. American Academy of Family Physicians. Policy statement of the American Academy of Family Physicians on thimerosal in vaccines, July 8, 1999. Available at http://www.aafp.org/policy/ camp/20.html. Accessed September 3, 1999.
4. CDC. Implementation guidance for immunization grantees during the transition period to vaccines without thimerosal, July 14, 1999. Available at http://www.cdc.gov/nip/news/ thimerosal-guidance.html. Accessed September 3, 1999.
5. Advisory Committee on Immunization Practices. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991;40(no. RR-13).
6. CDC. Update: recommendations to prevent hepatitis B virus transmission - United States. MMWR 1999;48:33-4.
7. CDC. Health information for international travel 1999-2000. Atlanta, Georgia: US Department of Health and Human Services, 1999:98-102.
8. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995;274:1201-8.